Novartis Under Investigation Over MS Drug Marketing

Law360, Washington (July 17, 2013, 6:38 PM EDT) -- The U.S. government is investigating whether Novartis AG employed illegal marketing practices and provided kickbacks to health care providers for using its multiple sclerosis drug Gilenya, the pharmaceutical company revealed Wednesday.

According to a regulatory filing with the U.S. Securities and Exchange Commission, the U.S. Attorney's Office for the Southern District of New York served the company with a civil investigative demand to look into the allegations just this month.

The office requested documents and information regarding Novartis' marketing practices for Gilenya and any payments it...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.